In this scenario, the combination of IDO1 inhibitors with immunotherapies and other anti-cancer drugs seems to be particularly encouraging and emphasizes the relevant role of tumor biology knowledge in the development of more efficient therapies. This evidence concerns the gene IDO1 and cancer.